Stay updated with breaking news from Accelerated Approval Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable saf...
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
BASEL (dpa-AFX) - Novartis (NVS) said that the U.S. Food and Drug Administration granted accelerated approval to Vijoice or alpelisib for the treatment of adult and pediatric patients 2 years of
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)